If you feel your psoriasis treatment is not producing what you seek here are 10 key factors that might be hindering your ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Compared with adalimumab, several biologic medications had superior safety profiles for the treatment of moderate to severe psoriasis.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...